Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

Haematologica

Volumn 97, Issue 12, 2012, Pages 1925-1928

  Arnulf, Bertrand ^a   Pylypenko, Halyna ^b   Grosicki, Sebastian ^c   Karamanesht, Ievgenii ^d   Leleu, Xavier ^e   van de Velde, Helgi ^f   Feng, Huaibao ^g   Cakana, Andrew ^f   Deraedt, William ^f   Moreau, Philippe ^h  

^a SAINT LOUIS HOSPITAL   (France)

^b Cherkassy Regional Oncology Dispensary ^*  (Ukraine)

^c Oddzial Hematologiczny ZSM   (Poland)

^d Kiev BMT Centre   (Ukraine)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^g JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^h NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Bortezomib; Intravenous; Multiple myeloma; Relapse; Subcutaneous; Survival

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; LOMUSTINE; MELPHALAN; PREDNISOLONE; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PYRAZINES; REMISSION INDUCTION; SURVIVAL RATE;

EID: 84868096248     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.067793     Document Type: Article

References (18)

1. Millennium Pharmaceuticals Inc. VELCADE ® (bortezomib) for Injection. Pre - scribing information. Cambridge, MA, USA. 2012; Issued January, Rev 13.
2. Janssen-Cilag International N.V. VELCA - DE® (bortezomib). Summary of Product Characteristics. Beerse, Belgium. 2009.
3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology™ Multiple Myeloma (V1.2012). Available at http://wwwnccnorg/professionals/physician_gls/PDF/myeloma.pdf
4. van de Donk NW, Lokhorst HM, Dimo-Poulos M, Cavo M, Morgan G, Einsele H, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev. 2011; 37(4):266-83.
5. Moreau P, Pylypenko H, Grosicki S, Kara-Manesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-40.
6. Greipp PR, San Miguel, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-20.
7. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemo - poietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5): 1115-23.
8. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348(26):2609-17.
9. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. Inter - national uniform response criteria for multiple myeloma. Leukemia. 2006;20(9): 1467-73.
10. Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86(1): 23-31.
11. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895-903.
12. Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23): 4745-53.
13. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet. 2010; 376(9758):2075-85.
14. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, et al. Borte - zomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28(30):4621-9.
15. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan andprednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13): 2259-66.
16. Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, de Paz R, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934-41.
17. Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, et al. Bortezomib-melphalanprednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalanprednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34):5101-9.
18. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-17.